title: [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
abstract: Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.
authors.forename: Wolfgang P
authors.initials: WP
authors.lastname: Fendler
authors.forename: Clemens
authors.initials: C
authors.lastname: Kratochwil
authors.forename: Hojjat
authors.initials: H
authors.lastname: Ahmadzadehfar
authors.forename: Kambiz
authors.initials: K
authors.lastname: Rahbar
authors.forename: Richard P
authors.initials: RP
authors.lastname: Baum
authors.forename: Matthias
authors.initials: M
authors.lastname: Schmidt
authors.forename: Andreas
authors.initials: A
authors.lastname: Pfestroff
authors.forename: Ulf
authors.initials: U
authors.lastname: Lützen
authors.forename: Vikas
authors.initials: V
authors.lastname: Prasad
authors.forename: Alexander
authors.initials: A
authors.lastname: Heinzel
authors.forename: Martin
authors.initials: M
authors.lastname: Heuschkel
authors.forename: Juri
authors.initials: J
authors.lastname: Ruf
authors.forename: Peter
authors.initials: P
authors.lastname: Bartenstein
authors.affiliation: Prof. Dr. Bernd Joachim Krause, Deutsche Gesellschaft für Nuklearmedizin e. V., Nikolaistr. 29, 37073 Göttingen, office@nuklearmedizin.de.
authors.forename: Bernd J
authors.initials: BJ
authors.lastname: Krause
mesh_terms: D004151:Dipeptides / Q000592:standards / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005858:Germany; D006573:Heterocyclic Compounds, 1-Ring / Q000592:standards / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium; D008297:Male; D009683:Nuclear Medicine / Q000592:standards*; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000532:radiotherapy* / Q000556:secondary*; D011829:Radiation Dosage; D011874:Radiometry / Q000592:standards*; D019275:Radiopharmaceuticals / Q000592:standards / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: C000610110:Pluvicto; D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; D019275:Radiopharmaceuticals; D008187:Lutetium; D017430:Prostate-Specific Antigen
keywords: Consensus; PSMA; lutetium; prostate cancer; radioligand therapy